Strand Announces Collaboration with Bio-Rad for its Predictive ADME Suite

11-Aug-2004

Bangalore, India. Strand Genomics, a Bangalore-based life sciences informatics company announced that it has entered into an collaborative agreement with Bio-Rad Laboratories, Inc. to integrate its predictive human pharmacokinetic models in Bio-Rad's KnowItAll® platform for in silico ADME/Tox assessment.

Strand's ADME-Predict(TM) models generate predictions for human pharmacokinetic parameters used in drug discovery, such as bioavailability, volume of distribution, plasma half-life, and protein binding when a user enters a chemical structure of a potential drug candidate into the system. Strand's prediction models, developed from studies on about 500 drugs, demonstrate accuracy of R-square values greater than 0.7 in validation tests.

"We have highly accurate models that can aid hit and lead generation and optimization," remarked Dr. Kas Subramanian, CSO, Strand. "We are pleased to combine this expertise and technology along with Bio-Rad's award-winning KnowItAll platform. This combined expertise will allow medicinal chemists and pharmacologists design and optimize leads and candidates that have the greatest chance of succeeding in the clinic."

"We look forward to working with Strand Genomics in moving forward to accelerate drug discovery. The addition of these predictors emphasizes Bio-Rad's continued commitment to offer the most comprehensive ADME/Tox prediction portfolio to the drug discovery community," commented Gregory M. Banik, Ph.D., General Manager, Informatics Division, Bio-Rad

https://www.analytica-world.com/en/news/39038/strand-announces-collaboration-with-bio-rad-for-its-predictive-adme-suite.html